Sulfatrim Pediatric Treatment Guidelines

Introduction to Sulfatrim Pediatric

Sulfatrim pediatric is recommended by the Centers for Disease Control and Prevention (CDC) for PCP prophylaxis in immunocompromised children, with a dosage of 150 mg trimethoprim with 750 mg sulfamethoxazole/m² body surface area, given 3 days per week 1

The American Academy of Pediatrics suggests the use of sulfatrim pediatric as an alternative to amoxicillin for the treatment of ear infections, such as otitis media, in children 2, 3
The CDC recommends sulfatrim pediatric for both treatment and prophylaxis of Pneumocystis jirovecii pneumonia in immunocompromised children 1
The Infectious Diseases Society of America recommends TMP-SMX for the treatment of Shigella spp. infections and non-typhoidal Salmonella infections in severe cases or patients with risk factors 4

The FDA-approved pediatric dosing for trimethoprim-sulfamethoxazole is based on the trimethoprim component, with a standard dosage of 8-12 mg/kg/day of trimethoprim component (40-60 mg/kg/day of sulfamethoxazole) divided into 2 doses given every 12 hours, and 15-20 mg/kg/day of trimethoprim component (75-100 mg/kg/day of sulfamethoxazole) divided into 3-4 doses for Pneumocystis jirovecii pneumonia treatment 1, 3
The American College of Physicians recommends TMP-SMX as a first-line treatment for acute uncomplicated cystitis when local resistance is <20%, with a dosage of 160/800 mg twice a day for 3 days 5
The standard dosage for adults is 160 mg TMP/800 mg SMX (double strength) twice a day 5
The dosage for PCP prophylaxis is 15-20 mg/kg/day of the TMP component, divided into 3-4 doses, or 150 mg TMP with 750 mg SMX/m² divided, given 3 days per week 6, 1

Trimethoprim/sulfamethoxazole is contraindicated in patients with known hypersensitivity to trimethoprim or sulfonamides, due to the risk of severe cutaneous reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, as recommended by the American Academy of Dermatology 7
It is also contraindicated in infants younger than 2 months due to the risk of kernicterus and immature drug metabolism, as recommended by the CDC 8, 1, 3
Patients with G6PD deficiency should use trimethoprim/sulfamethoxazole with caution, due to the risk of hemolytic anemia, as recommended by the CDC and the American Academy of Dermatology 1

Patients should be monitored for signs of hypersensitivity, skin eruptions, and hematologic alterations 7, 3
The CDC recommends regular monitoring of complete blood counts, renal function, and liver function during TMP-SMX treatment 1, 3
Common adverse effects include gastrointestinal symptoms and hypersensitivity reactions, as reported by the CDC and the American Academy of Dermatology 8, 3
Rare but serious adverse effects include Stevens-Johnson syndrome, toxic epidermal necrolysis, agranulocytosis, aplastic anemia, hepatic necrosis, and blood dyscrasias, as reported by the American Academy of Dermatology and the CDC 7, 3, 9

For patients with creatinine clearance 15-30 mL/min, the dosage should be reduced to half the usual dosage, and for creatinine clearance <15 mL/min, trimethoprim-sulfamethoxazole is not recommended, as recommended by the CDC and the American Academy of Dermatology 3
If trimethoprim/sulfamethoxazole is not tolerated, alternative treatments such as aerosolized pentamidine, dapsone, or pentamidine isethionate may be considered, as recommended by the CDC and the American Academy of Dermatology 8, 1
Patients should be advised to take the medication with food to decrease GI side effects, and to shake the liquid formulation well before measuring, as recommended by the CDC and the American Academy of Dermatology 9